BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update
13 août 2024 16h05 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem...
BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024
06 août 2024 16h05 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Aug. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based...
BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine
23 juil. 2024 07h10 HE
|
BioRestorative Therapies, Inc
- New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc....
BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
17 juin 2024 07h05 HE
|
BioRestorative Therapies, Inc
- Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) --...
BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice
24 mai 2024 19h45 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., May 24, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based...
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
30 avr. 2024 16h15 HE
|
BioRestorative Therapies, Inc
- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity - MELVILLE, N.Y., April 30, 2024 (GLOBE...
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
16 avr. 2024 07h45 HE
|
BioRestorative Therapies, Inc
— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or...
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants
03 avr. 2024 16h38 HE
|
BioRestorative Therapies, Inc
- Company is not offering shares pursuant to the registration statement - MELVILLE, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the...
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
11 mars 2024 16h15 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market
06 févr. 2024 08h05 HE
|
BioRestorative Therapies, Inc
MELVILEE, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...